➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

McKesson
Medtronic
Johnson and Johnson
Colorcon
Mallinckrodt
Moodys

Last Updated: September 16, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR PHOSLO

➤ Get the DrugPatentWatch Daily Briefing

« Back to Dashboard

All Clinical Trials for Phoslo

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00211939 ↗ CARE-2 (Calcium Acetate [PhosLo®]/Sevelamer[Renagel®] Evaluation Study 2) for Heart Calcification in Dialysis Patients Completed Nabi Biopharmaceuticals Phase 4 2005-01-01 The purpose of the study is to evaluate the effects of two phosphate binders, PhosLo and sevelamer, on heart calcification in dialysis patients. The study will use a non-invasive technique, electron beam computed tomography (CT) scanning, to measure calcium in the coronary arteries, the aortic valve, and the mitral valve.
NCT00211978 ↗ EPIC(Effect of PhosLo on Phosphorus Levels in Chronic Kidney Disease) Completed Nabi Biopharmaceuticals Phase 3 2005-05-01 The purpose of this study is to determine if calcium acetate (PhosLo) can control serum phosphorus in pre-dialysis patients with moderate to severe impairment of kidney function.
NCT00742820 ↗ Bioequivalence Study Comparing Calcium Acetate Oral Solution Versus Calcium Acetate Gelcaps in Healthy Volunteers Completed Fresenius Medical Care North America Phase 1 2008-08-01 To compare the bioequivalence of calcium acetate oral solution vs. calcium acetate gelcaps in healthy volunteers with calcium citrate as a positive control.
NCT01074125 ↗ A 4-Week Dose-Ranging and Efficacy Trial of KRX-0502 (Ferric Citrate) in Patients With End-Stage Renal Disease Completed Collaborative Study Group (CSG) Phase 3 2010-05-01 This is a research study for people with high blood phosphorus levels who are on dialysis. This medical condition can cause weakening of the bones and damage other organs. This can lead to many health problems, and sometimes death. Phosphorus is in much of the food we eat, and is helpful to us in small amounts. Patients with kidney failure have trouble getting rid of the phosphorus eaten in food. Dialysis can help remove some of the phosphorus, but often patients must take a phosphate binder like PhosLo®, Renagel®, or Renvela® to bring the blood phosphorus levels back to normal. The purpose of this study is to see if KRX-0502 (ferric citrate) is safe and effective as a phosphate binder.
NCT01074125 ↗ A 4-Week Dose-Ranging and Efficacy Trial of KRX-0502 (Ferric Citrate) in Patients With End-Stage Renal Disease Completed Keryx Biopharmaceuticals Phase 3 2010-05-01 This is a research study for people with high blood phosphorus levels who are on dialysis. This medical condition can cause weakening of the bones and damage other organs. This can lead to many health problems, and sometimes death. Phosphorus is in much of the food we eat, and is helpful to us in small amounts. Patients with kidney failure have trouble getting rid of the phosphorus eaten in food. Dialysis can help remove some of the phosphorus, but often patients must take a phosphate binder like PhosLo®, Renagel®, or Renvela® to bring the blood phosphorus levels back to normal. The purpose of this study is to see if KRX-0502 (ferric citrate) is safe and effective as a phosphate binder.
NCT01191255 ↗ A 58-Week Safety and Efficacy Trial of Ferric Citrate in Patients With ESRD on Dialysis Completed Keryx Biopharmaceuticals Phase 3 2010-10-01 This is up to a 58 week study comparing ferric citrate to active control for 52 weeks in ESRD dialysis patients, and subsequently comparing ferric citrate to placebo for 4 weeks.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Phoslo

Condition Name

Condition Name for Phoslo
Intervention Trials
Hyperphosphatemia 4
Kidney Failure 2
Hyperparathyroidism, Secondary 2
Calcinosis 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Phoslo
Intervention Trials
Hyperphosphatemia 4
Kidney Diseases 3
Kidney Failure, Chronic 3
Hyperparathyroidism, Secondary 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Phoslo

Trials by Country

Trials by Country for Phoslo
Location Trials
United States 36
Puerto Rico 2
Israel 1
Italy 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Phoslo
Location Trials
Texas 4
Ohio 3
Wisconsin 2
Tennessee 2
New York 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Phoslo

Clinical Trial Phase

Clinical Trial Phase for Phoslo
Clinical Trial Phase Trials
Phase 4 1
Phase 3 3
Phase 1 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Phoslo
Clinical Trial Phase Trials
Completed 5
Recruiting 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Phoslo

Sponsor Name

Sponsor Name for Phoslo
Sponsor Trials
Keryx Biopharmaceuticals 2
Nabi Biopharmaceuticals 2
Azienda Ospedaliera Sant'Anna 1
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Phoslo
Sponsor Trials
Industry 6
Other 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Express Scripts
Harvard Business School
Merck
Boehringer Ingelheim
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.